Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

28.28€

0.02 / 0.07%

2026-06-01 17:35 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

35,907,508
(March 31, 2026)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Leerink Partners

Marc Goodman

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

Degroof Petercam

David Seynnaeve

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Jean-Pierre Tabart

Documentation

May 2026

Investor Presentation

2025

CSR Report

Latest news

Videoconference and publication of annual financial results, Tuesday, June 16, 2026
May 28, 2026

Videoconference and publication of annual financial results, Tuesday, June 16, 2026

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
May 26, 2026

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
May 21, 2026

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
April 29, 2026

UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
April 22, 2026

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap